GCV-Induced Toxicity on Blood Cell Counts
| Platelets (×106) . | Erythrocytes (×106) . | Leukocytes (×103) . | ||||
|---|---|---|---|---|---|---|
| . | D0 . | D9 . | D0 . | D9 . | D0 . | D9 . |
| Nontransgenic | 1.10 ± 0.20 | 1.25 ± 0.4 | 10.26 ± 1.4 | 8.00 ± 0.75 | 11.53 ± 3.2 | 10.27 ± 3 |
| HαIIb-tk (1) | 1.15 ± 0.25 | 0.3 ± 0.25 | 10.2 ± 2.7 | 8.42 ± 1.59 | 10.6 ± 2.6 | 9.53 ± 2.65 |
| MαIIb-tk (1) | 1.02 ± 0.17 | 0.35 ± 0.13 | 9.95 ± 2.5 | 10.4 ± 0.6 | 9.26 ± 1.14 | 8.5 ± 1.6 |
| MαIIb-tk (3) | 1.25 ± 0.65 | 0.15 ± 0.12 | 10.9 ± 1.30 | 4.2 ± 1.9 | 11.4 ± 3.6 | 5.05 ± 3.75 |
| MαIIb-tk (4) | 1.05 ± 0.25 | 0.12 ± 0.41 | 10.45 ± 2.45 | 3.1 ± 1.3 | 11.27 ± 5.5 | 2.85 ± 2.6 |
| Platelets (×106) . | Erythrocytes (×106) . | Leukocytes (×103) . | ||||
|---|---|---|---|---|---|---|
| . | D0 . | D9 . | D0 . | D9 . | D0 . | D9 . |
| Nontransgenic | 1.10 ± 0.20 | 1.25 ± 0.4 | 10.26 ± 1.4 | 8.00 ± 0.75 | 11.53 ± 3.2 | 10.27 ± 3 |
| HαIIb-tk (1) | 1.15 ± 0.25 | 0.3 ± 0.25 | 10.2 ± 2.7 | 8.42 ± 1.59 | 10.6 ± 2.6 | 9.53 ± 2.65 |
| MαIIb-tk (1) | 1.02 ± 0.17 | 0.35 ± 0.13 | 9.95 ± 2.5 | 10.4 ± 0.6 | 9.26 ± 1.14 | 8.5 ± 1.6 |
| MαIIb-tk (3) | 1.25 ± 0.65 | 0.15 ± 0.12 | 10.9 ± 1.30 | 4.2 ± 1.9 | 11.4 ± 3.6 | 5.05 ± 3.75 |
| MαIIb-tk (4) | 1.05 ± 0.25 | 0.12 ± 0.41 | 10.45 ± 2.45 | 3.1 ± 1.3 | 11.27 ± 5.5 | 2.85 ± 2.6 |
Mean peripheral blood cell counts (±SD) of control nontransgenic, HαIIb-tk, and MαIIb-tk mice (n = 5), before (D0) and after 9 days (D9) of GCV administration (0.1 mg/day/g body weight). The counts shown are per μL of blood volume. The number in brackets refers to the integrated copies of the transgene.